Dr. Reddy’s Q1 Results Review: Systematix Maintains 'Hold' Rating On Weak U.S. Performance

Market: Dr Reddy’s bullish on global prospects

Alvotech partnership to co-develop biosimilar candidate to Keytruda® Hyderabad-headquartered Dr. Reddy’s Laboratories Ltd (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) remains bullish on global business prospects as it reported 11% Y-on-Y increase in revenue to Rs.85.452 billion for Q1 2026, which ended 30 June 2025. But Q-on-Q it was flat. Profit […] Source

Dr. Reddy’s Q1 Results Review: Systematix Maintains 'Hold' Rating On Weak U.S. Performance

Dr. Reddy's has identified multiple levers - Cost control, generic Semaglutide launch in Canada and ramp up in CDMO/Consumer business to offset the erosion. Ramp up in biosimilar business should reflect from FY28 onwards. The cost control lever is likely to be one of last resort, in case the other levers fail to play out as expected.NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from acro…

India's Dr Reddy's plans to launch generic obesity drugs in 87 countries next year, CEO says

FILE PHOTO: Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams//File Photo HYDERABAD (Reuters) -Dr Reddy’s Laboratories plans to launch a cheaper copycat version of Novo Nordisk’s blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker’s CEO, Erez Israeli, said on Wednesday. Drugmakers are racing to get a share of the global obesity drug market, expected …

Dr Reddy's Labs Q1 Results: Net profit rises just 1.4% YoY to ₹1,409 crore; revenue surges 11%

Source: Live Mint Dr Reddy’s Labs Q1 Results: Leading pharmaceutical company Dr Reddy’s Laboratories announced earnings for the April to June quarter of the financial year 2025-26 on Wednesday, July 23. The company reported a consolidated net profit growth of 1.4% to ₹1,409 crore in Q1FY26 compared to ₹1,392 crore posted in the year-ago period. The pharma major’s revenue from operations in the June-ended quarter stood at ₹8,572 crore, which wa…

Dr Reddy’s kicks off India big pharma earnings with narrow profit miss - Regional Media News

(Reuters) -Indian generic drugs maker Dr Reddy’s Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it struggled with pricing pressure on drugs and stiff competition in its key North America market. The firm, one of the top three drugmakers in India by revenue, has been strengthening its consumer healthcare portfolio, which includes over-the-counter medicines, nutrition supplements, as it looks to build a strong …